Gennova Biopharmaceuticals Ltd., the Pune-based biotechnology company, which has developed India’s first mRNA-based COVID-19 vaccine, submitted the proposed Phase II and Phase III study entitled ‘A prospective, multicentre, randomized, active-controlled, observer-blind, Phase II study seamlessly followed by a Phase III study to